EAST NORRITON, Pa., Sept. 18 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-tissues, today announced that the results of a preclinical research study conducted with its Tengion Neo-Bladder Augment(TM) were published in the September issue of the Regenerative Medicine, Vol. 3, Issue 5. The paper, “Long-term durability, tissue regeneration and neo-organ growth during skeletal maturation with a Neo-Bladder Augmentation Construct” was co-authored by Tengion scientists Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., John W. Ludlow, Ph.D., Richard Payne, Ph.D., Belinda J. Wagner, Ph.D., and Timothy A. Bertram, D.V.M., Ph.D. along with Gordon McLorie, MD from Wake Forest University Baptist Medical Center. The article can be accessed via the website http://www.futuremedicine.com/doi/abs/10.2217/17460751.3.5.671
The preclinical study, in which either a Neo-Bladder Augment or the subject’s own native urinary bladder was surgically implanted following an 80% cystectomy and evaluated clinically at one, three, six, nine, 12, 18 and 24 months - showed that the Tengion Neo-Bladder Augment regained and maintained native bladder histology by three months. The study also demonstrated that the Neo-Bladder Augment regained baseline capacity at three to six months and baseline compliance by 12-24 months. Importantly, the Neo-Bladder Augment continued to adapt in size and function with overall animal growth, or skeletal maturation.
“The results of this study are very encouraging for our overall Neo-Bladder Augment program and, specifically, for our ongoing Neo-Bladder Augment pediatric clinical trial. The children with spina bifida in that trial are continuing to grow and mature and our goal is for the Neo-Bladder Augment to demonstrate durability and the ability to adapt to growth-related changes - as it has done in this pre-clinical model,” said Dr. Bertram, Senior Vice President, Science and Technology of Tengion, “Tengion is truly excited to continue to share positive research results that help to further advance our neo-organ pipeline, and continue to validate our Autologous Organ Regeneration Platform(TM).”
About Tengion
Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient’s own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body’s innate ability to regenerate. Tengion’s product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.
CONTACT: Gary Sender of Tengion Inc., +1-267-960-4802; Keri Mattox of Pure
Communications, +1-215-791-0105
Web site: http://www.tengion.com/
